United Therapeutics Corporation
UTHR
Rangering i aksjer
#1030
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Aksjekurs
$533.18
Sist synkronisert: 2026-10-16
Markedsverdi
$22.87B
Endring (1 dag)
-1.54%
Endring (1 år)
23.04%
Land
US
Handel United Therapeutics Corporation (UTHR)
Kategori
Healthcare
Driftsmargin for United Therapeutics Corporation (UTHR)
Driftsmargin per October 2026 TTM: 44.49%
Ifølge United Therapeutics Corporation sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 44.49%. Ved slutten av 2023 hadde selskapet en driftsmargin på 50.91%.
Historikk for driftsmargin for United Therapeutics Corporation fra 2000 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 44.49% | -7.04% |
| 2024 | 47.86% | -5.99% |
| 2023 | 50.91% | 0.61% |
| 2022 | 50.60% | 53.43% |
| 2021 | 32.98% | -17.59% |
| 2020 | 40.02% | -409.03% |
| 2019 | -12.95% | -126.17% |
| 2018 | 49.48% | 4.76% |
| 2017 | 47.23% | -28.88% |
| 2016 | 66.41% | 39.25% |
| 2015 | 47.69% | 14.04% |
| 2014 | 41.82% | 59.68% |
| 2013 | 26.19% | -43.10% |
| 2012 | 46.03% | 7.65% |
| 2011 | 42.76% | 57.44% |
| 2010 | 27.16% | 286.34% |
| 2009 | 7.03% | -124.12% |
| 2008 | -29.15% | -1,074.92% |
| 2007 | 2.99% | -83.54% |
| 2006 | 18.16% | -50.92% |
| 2005 | 37.00% | 106.13% |
| 2004 | 17.95% | -183.06% |
| 2003 | -21.61% | -63.84% |
| 2002 | -59.77% | -92.70% |
| 2001 | -818.93% | -79.41% |
| 2000 | -3,977.08% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -99.13% |
US
|
|
| -149.01% | -103.35% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.35% |
NL
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.